The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)
Author(s): 
Pages: 25-27
Year: Issue:  1
Journal: CHINESE JOURNAL OF HEMATOLOGY

Keyword:  白血病早幼粒细胞急性维甲酸砷剂;
Abstract: 目的观察全反式维甲酸(ATRA)联合三氧化二砷(As2O3)治疗初发急性早幼粒细胞白血病(APL)的完全缓解(CR)率和融合基因PML-RARα转阴情况.方法 ATRA 25 mg*m-2*d-1、As2O3 0.16 mg*kg-1*d-1联合治疗初发APL直至CR.根据外周血白细胞计数、维甲酸综合征以及肝功能变化调整ATRA和As2O3的剂量.观察CR率、获得CR和融合基因PML-RARα转阴所需的时间、不良反应及近期缓解时间.结果 31例初发APL患者早期死亡2例,29例获CR,CR率93.5%,获得CR的平均时间为(25.1±3.9) d.66.5%患者在治疗开始后出现白细胞升高,65.5%出现肝功能异常,多在As2O3减量或停用后1周内恢复.所有患者初发时均为PML/RARα阳性,CR时10.3%转阴,巩固治疗后检测的13例中10例(77.0%)转阴.至今29例获CR的患者仍处CR状态(1~8个月).结论 ATRA联合As2O3治疗初发APL疗效好,不良反应少.长期CR时间需要进一步观察.
Related Articles
No related articles found